We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Insys Therapeutics may soon turn the page on the high-profile federal probe into its Subsys sales practices—a probe that has already snared a half-dozen former Insys managers now facing criminal charges.